In the present invention, an attempt made to evaluate the correlation between in vitro dissolution and in vivo dissolution, by incorporating enzymes to match the human body physiol. conditions. Dipyridamole Extended Release Capsules evaluated for dissolution in simulated fasting change over condition & simulated fed change over condition to synchronize the human body condition. In fasting change over condition, the dissolution is performed by using simulated dissolution media of pH 1.6 Fasted state simulated gastric fluid for 1 h, followed by pH 6.0 Fasted state simulated intestinal fluid for 2 h followed by pH 7.2 Fasted state simulated intestinal fluid for 2 h, followed by pH 6.5 Fasted state simulated intestinal fluid for 4 h, followed by pH 6.8 Fasted state simulated intestinal fluid for 1 h. In Fed change over condition, the dissolution is performed by using simulated dissolution media of pH 5.0 Fed state simulated gastric fluid for 1 h, followed by pH 5.8 Fed state simulated intestinal fluid for 2 h, followed by pH 7.2 Fed state simulated intestinal fluid for 1 h, followed by pH 6.5 Fed state simulated intestinal fluid for 5hrs followed by fed state simulated intestinal fluid pH 6.8 for 1 h. The dissolution is performed for marketed product in the simulated condition, and found comparable. In addition to that the effect of surfactant in dissolution profiling is evaluated by using sodium lauryl sulfate as surfactant with different concentration levels, by suing 0.1M pH 5.5 Phosphate buffer. No effect is observed up to 1.0% of sodium lauryl sulfate concentration in dissolution medium. Effect of agitation speed on dissolution evaluated and the agitation above 150 RPM is having effect on dissolution, due to centripetal force, so the dissolution values observed is lesser than 100-RPM values.